An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab.
Osteoporosis is responsible for a significant burden both individually and socially, but is readily treated with antiresorptive agents and mineral supplementation. However, long-term usage of these agents, notably bisphosphonates, is rarely associated with atypical fractures. Denosumab is a monoclonal antibody that reduces osteoclast activity and thus increases bone mineral density. In this case report, we present a 78-year-old woman with a background of rheumatoid arthritis and osteoporosis who presented with an atypical diaphyseal femoral fracture.
Department of Rheumatology, Worthing Hospital, Worthing, UK.
J
J
Villiers
Department of Orthopaedic Surgery, Worthing Hospital, Worthing, UK.
D W
DW
Clark
Department of Radiology, Worthing Hospital, Worthing, UK.
T
T
Jeswani
Department of Rheumatology, Worthing Hospital, Worthing, UK.
S
S
Webster
Department of Rheumatology, Worthing Hospital, Worthing, UK.
A L
AL
Hepburn